CDK4 and breast cancer: The aim of this review is to summarize the pharmacological background of CDK4/6 inhibitors (CDK4/6i), the latest evidence of their efficacy for the treatment of BC, their potential use in combination with other targeted therapies and the role of predictive biomarkers, focusing on affinities and differences among these three agents.